Cigarette smoke is a strong risk factor for cardiovascular disease. However, the underlying molecular mechanisms that lead to cigarette smoke-associated cardiovascular disease remain elusive. With functional and molecular methods, we demonstrate for the first time that lipid-soluble cigarette smoke particles (dimethylsulfoxide-soluble cigarette smoke particles; DSP) increased the expression of endothelin type B (ET B ) receptors in arterial smooth muscle cells. The increased ET B receptors in arterial smooth muscle cells was documented as enhanced contractility (sensitive myograph technique), elevated levels of ET B receptor mRNA (quantitative real-time PCR), and protein expressions (immunohistochemistry and Western blotting). Intracellular signaling was studied with Western blotting and phosphoELISA; this revealed that DSP induced extracellularregulated protein kinases 1 and 2 (ERK1/2), p38, and nuclear factor-kappaB (NF-kB) phosphorylation within 3 h. Blocking ERK1/2, p38, or NF-kB activation by their specific inhibitors significantly attenuated the DSP-induced upregulation of ET B receptor-mediated contraction and both ET B receptor mRNA and protein expression. In addition, dexamethasone abolished the DSP-induced upregulation of ET B receptor-mediated contraction.
There is abundance of evidences that demonstrate that cigarette smoke, either by smoking per se or following passive exposure, is a strong risk factor linked to high incidence of cardiovascular disease. Smoking per se results in 5 million premature deaths worldwide annually. Interestingly, the majority of these are caused by cardiovascular events (Lightwood, 2003) .
In a previous study, we found that the lipid-soluble particles from cigarette smoke dimethylsulfoxide-soluble cigarette smoke particles (DSP) reduce the vasodilator function of vascular endothelial cells (VECs) via decreasing in the nitric oxide (NO)-mediated and the endothelium-derived hyperpolarization factormediated vasodilatations in man and rat (Zhang et al., 2006) . Recently, we have observed that DSP, at a concentration equivalent to the plasma level seen in smokers, induced upregulation of thromboxane A 2 (TP) receptors in vascular smooth muscle cells (VSMCs) via posttranscriptional mechanism, mainly through enhanced translation of TP receptors (Zhang et al., 2008) . Removal of the endothelium did not affect TP receptor-mediated contraction (Zhang et al., 2008) , suggesting that the TP receptors on the VECs were not involved in the DSP effects. Similarly, organ culture of rat mesenteric arteries induces enhanced endothelin type B (ET B ) receptormediated contraction, and the enhanced contraction is unaffected by removal of the endothelium (Adner et al., 1998a) . More importantly, upregulation of the ET B receptor expression on the VSMCs is seen in cardiovascular disease (Li et al., 2007; Iwasa et al., 1999; Stenman et al., 2002) . During organ culture of venous segments, the phenomenon of the ET B receptor upregulation is also induced on the VSMCs of the vein with a strong contraction mediated by the ET B receptors (Adner et al., 1998b) . However, the underling molecular mechanisms that are responsible for the ET B receptor upregulation are still not fully understood. The present study was designed to test the novel hypothesis that DSP increases the expression of ET B receptors on the VSMCs through activation of intracellular mitogenactivating protein kinases (MAPKs) and transcription factor nuclear factor-kappaB (NF-jB) inflammatory signal transduction pathways.
In fresh arteries, the endothelin type A (ET A ) receptors are located on VSMCs and mediate contraction, while the ET B receptors are present on the endothelium and mediate vasodilatation via the release of nitric oxide (NO) and prostacyclin (Kedzierski and Yanagisawa, 2001) . In experimental cerebral ischemia, however, the contractile ET B receptor phenotype is expressed on VSMCs and mediates strong vasoconstriction in the ischemic cerebral artery (Stenman et al., 2002) . Increased expression of ET B receptors in VSMCs is also found in atherosclerotic plaques and neointimas (Iwasa et al., 1999) . Thus, the expression of ET B receptors in VSMCs is considered as an important event in the development of cardiovascular disease.
We have observed that VSMC ET B receptor upregulation can be induced by organ culture of arterial rings in serum-free medium (Adner et al., 1996) . This ET B receptor upregulation involves specific MAPK (Uddman et al., 2003) . The present study demonstrates for the first time that during the organ culture of the arterial rings in the presence of DSP results in further enhanced expression of contractile ET B receptors in VSMCs via activation of the MAPK extracellular-regulated protein kinases 1 and 2 (ERK1/2) and p38, as well as the downstream transcription factor NF-jB inflammatory signal transduction pathways, subsequently resulting in upregulation of ET B receptors. Understanding the underlying molecular mechanisms that are responsible for smoking-associated cardiovascular disease may provide novel options for the treatment.
METHODS
Extraction of DSP. Cigarettes (Marlboro, 0.8 mg nicotine per cigarette) were ''smoked'' by an aspirator, and the smoke was directed through a cotton wool filter. The retained smoke particles from three cigarettes in the filter were dissolved in either 1 ml dimethyl sulfoxide (DMSO) (DSP) (Zhang et al., 2006) or in 1 ml distilled water water-soluble cigarette smoke particles (WSP) and were diluted to a standard nicotine content of 0.1 mg/ml; these stock solutions were kept at À20°C for all subsequent experiments.
Tissue preparation and organ culture procedure. Sprague-Dawley rats (body weight 300-350 g) were anaesthetized with CO 2 and exsanguinated. The superior mesenteric artery was gently removed and freed of adhering tissue under a dissection microscope. The endothelium was denuded by perfusion of the vessel for 10 s with 0.1% Triton X-100 followed by another 10 s with a physiologic buffer solution (Hamel et al., 1987) . The vessels were then cut into 1-mm long cylindrical segments and incubated for 24 or 48 h at 37°C in humidified 5% CO 2 in air. The resulting cell culture was performed in a 24-well plate, with two segments per well, containing 1 ml Dulbecco's-modified Eagle's medium containing L-glutamine (584 mg/l) that was supplemented with penicillin (100 U/ml) and streptomycin (100 lg/ml) (Adner et al., 1996) . Experiments were performed in an organ culture of arterial segments in the presence of 0.2 ll/ml of DSP or DMSO (control). For Western blots, six rats were sacrificed per time point, and the artery segments were cultured as explained above for 0, 1, 3, 6, and 24 h. The experimental protocol was approved by Lund University Animal Ethic's Committee (M217-03).
Ex vivo pharmacology. Fresh or incubated, the VSMC ring segments were immersed in temperature-controlled (37°C) myographs (Organ Bath Model 700MO, J.P. Trading, Aarhus, Denmark) containing 5 ml bicarbonate buffer solution. The solution was continuously aerated with 5% CO 2 in O 2, resulting in a pH of 7.4. The VSMC ring segments were mounted for continuous recording of isometric tension with the Chart software (AD Instruments, Hastings, UK). A resting tone of 2.5 mN was applied to each segment, and the segments were allowed to stabilize at this tension for at least 1.5 h before exposure to a potassium-rich (60mM K þ ) buffer solution with the same composition as the standard solution, except that NaCl was replaced by an equimolar concentration of KCl. The potassium-induced contraction was used as a reference for contractile capacity, and the segments were used only if potassium elicited reproducible responses over 1.0 mN. Concentration-response curves for sarafotoxin 6c (S6c, selective ET B receptor agonist) were obtained by cumulative administration of the reagent (Adner et al., 1996) . The detailed protocol has been shown, and the receptors have been characterized previously (Adner et al., 1998a) . S6c was demonstrated to selectively activate ET B receptors (Adner et al., 1998b) .
Real-time reverse transcription-PCR. VSMCs were isolated from fresh or cultured artery segments. Total RNA extracted from the VSMCs was reversely transcribed to cDNA (Zhang et al., 2008) . The real-time quantitative PCR was performed with the GeneAmp SYBR Green PCR kit in a GeneAmp 7300 sequence detection system (Applied Biosystems, Foster City, CA) (Zhang et al., 2008) . Specific primers for the rat ET B receptor (GenBank accession no. NM_017333) were designed as follows-ET B receptor: forward: 5#-GATACGAC-AACTTCCGCTCCA-3# and reverse: 5#-GTCCACGATGAGGACAATGAG-3#.
Elongation factor-1 (EF-1, GenBank accession no. NM_175838) and glyceraldehyde 3-phosphate dehydrogenase (GAPDH, GenBank accession no. NM_017008) mRNA were used as references. The EF-1 and GAPDH primers were designed as follows-EF-1: forward: 5#-GCAAGCCCATGTGTGTT-GAA-3# and reverse: 5#-TGATGACACCCACAGCAACTG-3# and GAPDH: forward: 5#-GGCCTTCCGTGTTCCTACC-3# and reverse: 5#-CGGCATGTCAGATCCACAAC-3#.
Immunohistochemistry. Following organ culture in the presence of DMSO or DSP (0.2 ll/ml), the arterial segments were fixed, frozen in Tissue-Tek (Sakura Finetek Europe B.V., Zoeterwoude, Netherlands), cut at 10-lm thickness, and mounted on SuperFrost Plus slides (Menzel GMBH & COKG, Braunschweig, Germany) (Zhang et al., 2008) . Immunohistology staining with a specific polyclonal antibody against rat ET B receptor (Alexis Biochemicals, Lausen, Switzerland) and a secondary antibody donkey antisheep IgG conjugated to fluorescein isothiocynate (Alexis Biochemicals) was used to demonstrate ET B receptor proteins. The stained arterial segments were observed under a confocal microscope (Nikon, C1plus, Nikon Instruments, Melvile, NY) and analyzed by Image J software (http://rsb.info.nih.gov/ij) (Vikman et al., 2006) . The fluorescence intensity was measured on the smooth muscle cells. For each vessel, six randomly selected sections were assessed. In each section, the fluorescence intensity was measured at 20 preset areas, and the mean fluorescence intensity was obtained from six vessels.
Western blot. After organ culture, vessels were frozen in liquid nitrogen and homogenized in cell extract denaturing buffer (BioSource, Invitrogen, Carlsbad, CA) containing a phosphatase inhibitor cocktail and protease inhibitor cocktail (Sigma, St. Louis, MO). Protein concentration was measured with a Bio-Rad protein analysis kit and TECAN infinite M200. Proteins (40 lg) were loaded and separated on 4-15% Ready Gel Precast Gels (Bio-Rad, Life Science Research, Hercules, CA), followed by probing with the One-Step Complete Western Kit (GenScript Corporation, Piscataway, NJ) according to the manual. Briefly, membranes were incubated with pretreat solution on a shaker for 5 min at room temperature and then with a primary antibody overnight at 4°C. After washing three times for 10 min, the membranes were developed with working solution (LumiSensor A þ B) for 3 min, visualized using a Fujifilm LAS-1000 luminiscent image analyzer (Stamford, CT), and then analyzed with Image Gauge Ver. 4.0 (Fuji Photo Film Co., Ltd, Japan). The antibodies for phospho-p44/42 MAP kinase (Thr202/Tyr204), phosphop38 MAP kinase (Thr180/Tyr182), phospho-NF-jB p65 (Ser536), and b-actin were from Cell Signaling Technology (Beverly, MA). The ET B antibody was purchased from Abcam (Cambridge, UK). All antibodies were used at 1:1000, and the experiments were repeated three times.
PhosphoELISA. VSMCs were isolated at 4°C from arterial segments and homogenized. Phosphorylated ERK1/2 was measured using a PhosphoELISA assay kit (BioSource International, Inc., CA) following the manufacturers' instructions (Luo et al., 2006) . Chemicals and drugs. Selective ET B receptor agonist S6c, inhibitors for ERK1/2 (PD98059 and U0126), p38 (SB203580 and SB239063) and NF-jB (wedelolactone and IMD-0354), nonselective NF-jB and activated protein-1 SMOKE PARTICLES UPREGULATE ET B RECEPTORS 547 (AP-1) inhibitor dexamethasone, and nicotine were obtained from Sigma (Sigma, St. Louis, MO). S6c was dissolved in 0.1% bovine serum albumin. Dexamethasone and nicotine were confected with distilled water. Other reagents were dissolved in DMSO.
Data analysis. All data are expressed as mean values ± SEM. The responses of S6c are presented as a percentage of contraction to 60mM K. The amount of receptor mRNA relative to the internal control is expressed as a percentage of the control group. Statistical analysis was performed using one-way ANOVA and either Dunnet's post-test or two-tailed unpaired Student's t-test with Welch's correction. A p-value less than 0.05 was considered to be significant.
RESULTS

DSP Enhances ET B Receptor Upregulation
Fresh mesenteric artery ring segments showed a weak contractile response to S6c (<5% of K þ -induced contraction). Organ culture of the ring segments for 24 or 48 h resulted in markedly enhanced contraction induced by S6c (selective agonist for ET B receptor) (Figs. 1A and 1C) . The K þ -induced contraction did not differ between the groups. There was a significant increase in the contractile response to S6c in arterial segments exposed to DSP (0.2 or 0.4 ll/ml) for 24 or 48 h (Figs. 1A-C) as compared to control DMSO (p < 0.05). This suggests that the organ culture initiates the process of ET B receptor upregulation, and DSP accelerates this process. A concentration of 0.4 ll/ml DSP (for 24 h, Fig. 1B ) caused a smaller contractile response to S6c as compared with 0.2 ll/ ml incubation, suggesting the possible toxic effect of the high concentration of DSP to the VSMCs. Organ culture in presence of similar concentrations of DMSO as contained in DSP did not affect the contractile response to S6c. Removal of the endothelium did not affect the DSP effects. IRL2500 (10 À5 mol/l), a specific ET B receptor antagonist, blocked the contractile response to S6c with a pA 2 value of 8.04, demonstrating that the contraction was mediated by ET B receptors. In contrast, the extracted water-soluble cigarette smoke particles (WSP) (0.2 ll/ml) or nicotine alone (0.02 lg/ml, equivalent concentration of nicotine as in DSP) had no effects on the ET B receptor-mediated contraction (control E max 41±8% vs. WSP E max 48±11% and nicotine E max 42±11%; n ¼ 8 in each group, and p > 0.05).
In addition, ET A receptor-mediated contraction was examined after ET B receptors had been desensitized (Zhang et al., 2004) . The results showed that DSP enhanced the ET A receptor-mediated contraction with an increased E max from 260±3% to 548±7% (n ¼ 8, p < 0.001). However, angiotensin II-induced contraction was not affected by DSP.
ET B receptor mRNA expression was assessed using realtime PCR. Organ culture of vessel segments in the presence of DSP (0.2 ll/ml) for 24 h enhanced the expression of ET B receptor mRNA in the VSMCs, compared with control (p < 0.001) (Fig. 1D) .
Immunohistochemistry using specific antibodies against ET B receptors demonstrated that the ET B receptor protein was expressed in the VSMCs (Fig. 2A) , and this was increased after exposure of the segments to DSP (Figs. 2B and 2C ), compared with DMSO (control, p < 0.001). The enhanced ET B receptor protein expression by DSP in VSMCs was further demonstrated by Western blot (Figs. 4A and 4E ).
DSP-induced Phosphorylation of MAPK ERK1/2, p38, and NF-jB
To explore intracellular signal transduction invoked by the smoke particles, we studied phosphorylated ERK1/2 (pERK1/2), p38 (pp38), and NF-jB (pNF-jB p65) by Western blot analysis of extracts of arterial smooth muscle ring segments cultured with DMSO (0.2 ll/ml, control) or with DSP (0.2 ll/ml) for 0, 1, 3, 6, or 24 h. Organ culture with DMSO per se significantly activated pERK1/2, pp38, and pNF-jB p65 proteins with slightly different patterns. pERK1/2 was activated early (1 h), remained high until 6 h, and decreased slightly at 24 h (Fig. 3A) . pp38 and pNF-jB p65 increased more slowly and reached their highest levels at 6-24 h (Fig. 3A) . DSP further enhanced the phosphorylation of the previous three signal proteins (Fig. 3A) : for pERK1/2 at 1-6 h (Fig. 3B ), pp38 at 3-24 h (Fig. 3C) , and pNF-jB p65 at 1-3 h (Fig. 3D) . The increased phosphorylation of ERK1/2 by DSP is further confirmed by quantitative phosphoELISA measurements (Fig. 4F) .
Specific ERK1/2 inhibitors PD98059 and U0126 significantly suppressed ERK1/2 activation (Figs. 4A and 4B) but had no effect on p38 (Figs. 4A and 4C ). The activity of p38 (Figs. 4A and 4C), but not ERK1/2 (Figs. 4A and 4B), was inhibited by incubation with the p38 inhibitors SB203580 and SB239063. For pNF-jB p65, its specific inhibitors (IMD-0354 and wedelolactone) had a weak effect, and only IMD-354 showed significant inhibitory effects (Figs. 4A and 4D), although both IMD-0354 and wedelolactone totally inhibited the DSPinduced upregulation of ET B receptor protein (Figs. 4A and 4E ). All the specific inhibitors for ERK1/2 (PD98059 and U0126), (Fig. 4E) , respectively, but surprisingly, they did not markedly reduce the phosphorylation of NF-jB p65 protein in the VSMCs (Fig. 4D) .
PhosphoELISA quantitative analysis showed that in the presence of specific ERK1/2 inhibitors (PD98059 and U0126), the DSP-induced ERK1/2 phosphorylation (Fig. 4F) was reduced by more than 60% and 80%, respectively (Fig. 4G) .
Inhibition of Intracellular Signal Transduction Attenuates DSP-enhanced Upregulation of ET B Receptors
Following 24 h of co-incubation with DSP together with specific inhibitors for ERK1/2 (PD98059 and U0126, Figs. 5A-C), p38 (SB203580 and SB239063, Fig. 5D-F) , or NF-jB (IMD-0354 and wedelolactone, Figs. 5G-I), respectively, resulted in markedly reduced DSP-enhanced contractile responses to S6c. The E max of contraction was depressed by inhibition of ERK1/2 (Fig. 5C), p38 (Fig. 5F ), or NF-jB (Fig. 5I) . However, a c-Jun N-terminal protein kinase (JNK) inhibitor (SP600125) did not modify the DSP effects on S6c responses (DSP plus SP600125, E max ¼ 175 ± 26% vs. DSP plus vehicle, E max ¼ 199 ± 17%, n ¼ 8, p > 0.05). Dexamethasone, an anti-inflammatory agent, abolished the DSP-enhanced contractile responses to S6c (Fig. 5J) .
In parallel, we examined ET B receptor mRNA and protein expression in the VSMCs as measured by real-time PCR and Western blot analysis, respectively. We observed that the initial increases in ET B mRNA expression (Fig. 1D ) and in protein expression (Fig. 2B) were abolished by the inhibitors for ERK1/2, p38, and transcription factor NF-jB (Figs. 5K, L and 4E), respectively. The reduction of ET B receptor-mediated contraction paralleled the reduced expression of the ET B receptor mRNA (Figs. 5K and 5L) and protein (Fig. 4E) .
DISCUSSION
Cigarette smoke is a strong risk factor for cardiovascular disease. Studies have demonstrated that cigarette smoking acutely increases aortic stiffness and blood pressure in the smokers and the effects persist longer in smokers with hypertension than in the smokers without hypertension (Rhee et al., 2007) . The stiffness of arteries is more prominent in chronic smokers (Kim et al., 2005) . Cigarette smoking also causes immediate constriction of the coronary arteries with an increase in coronary resistance (Quillen et al., 1993) . These acute hemodynamic effects may contribute to the adverse cardiovascular consequences of cigarette smoking. In stroke patients, cigarette smoking significantly increases the risk of acute attacks, and the risk is further increased in passive smokers (Bonita et al., 1999) . A population-based cohort study in middle-aged adults concluded that both active and passive smoking are associated with the progression of atherosclerosis and this is of particular concern for patients with diabetes and hypertension (Howard et al., 1998) . However, the underlying molecular mechanisms that lead to cigarette smoke-associated cardiovascular disease are poorly understood. The present study demonstrated that DSP can enhance ET B receptor upregulation (at mRNA, protein, and functional levels) in VSMCs via activation of intracellular MAPK (ERK1/2 and p38) and the downstream transcriptional factor NF-jB inflammatory signal pathways. Specific blockage of the intracellular signal pathways amends DSP-induced upregulation of ET B receptors.
The ET B receptor upregulation in the VSMCs links to cardiovascular disease. In hypertensive rats (Li et al., 2007) and in hypertensive patients (Li et al., 2007; Lind et al., 1999; Nilsson et al., 2008) , there is an upregulation of ET B receptors in resistance arteries. In experimental cerebral ischemia, the ET B receptors are expressed on the VSMCs and mediates strong vasoconstriction of the ischemic cerebral artery (Stenman et al., 2002) . The increased expression of ET B receptors in VSMCs has also been found in atherosclerotic plaques and neointimas (Iwasa et al., 1999) . On the other hand, the endothelium is considered as the primary target of cardiovascular risk factors. We have observed that DSP attenuates the endothelium-dependent relaxation and NO pathway (Zhang et al., 2006) . In cell culture, DSP decreases the prostacyclin (prostagladin I 2 ) production from the VECs (Xu et al., 1992) . In a human study, cigarette smoking leads to reduced relaxant responses of cutaneous microcirculation . In coculture models of the VSMCs with the endothelial cells, DSP via the VEC promotes the VSMC proliferation (Xu et al., 1991) . In order to specifically address one aspect of the complicated interplay between the toxic effects of DSP and the arterial cells, the present study was designed to focus on the VSMCs. The functional alterations associated with the enhanced expression of ET B receptors and dysfunction of endothelium by DSP may induce abnormal VSMC tone (via increased contraction and/or reduced relaxation) and enhanced VSMC proliferation. These functional alterations result in structure changes in the vascular wall associated with adverse remodeling, plaque formation, and in clinical sequelae such as myocardial infarction, stroke, and ischemia.
Our studies suggest that the intracellular MAPK and NF-jB inflammatory signal transducion pathways are involved in the upregulation of ET B receptors in the VSMCs. In experimental rat subarachnoid haemorrhage (SAH), intracranial administration of specific inhibitors for MAPK ERK1/2 attenuates the expression of ET B receptors and prevents blood flow reduction after SAH (Ansar et al., 2007) . In the present study, Western blot and PhosphoELISA use antibodies against specific phosphorylated (activated) key signal transduction molecules in order to elucidate the intracellular events activated by DSP. In a series of tests with a set of specific inhibitors for ERK1/2 (PD98059) (Alessi et al., 1995) and U0126 (Duncia et al., 1998) , p38 (SB203580) (Baldassare et al., 1999) and SB239063 (Underwood et al., 2000) , JNK (SP600125) (Bennett et al. 2001 ) and transcriptional factor NF-jB (IMD-0354) (Tanaka et al., 2005) and wedelolactone (Kobori et al., 2004) , we obtained data that link the intracellular events with the upregulation of ET B receptors in the VSMCs under DSP stimulation. We revealed that ERK1/2, p38, and NF-jB inhibitors significantly attenuated the additional DSP-induced upregulation of ET B receptors, while the JNK inhibitor had no effect. The specific inhibitors for ERK1/2, p38, or NF-jB inhibited the DSP-induced ET B receptor protein expression, suggesting that intracellular MAPK ERK1/2, p38, and NF-jB signal transduction pathways are involved. Surprisingly, the inhibitors did not markedly reduce the NF-jB p65 protein activity (phosphorylation) in the VSMCs. This suggests that their mode of inhibiting ET B receptor expression were not through the NF-jB p65 protein phosphorylation or these inhibitors might directly prohibit the translocation of pNF-jB p65 into the cell nucleus, the key step for the downstream signaling of ERK1/2 and p38 MAPK (Hoffmann et al., 2006) . The inhibitors used in the present study for blocking NF-jB signal transduction pathways have been demonstrated to prevent the phosphorylation and degradation of IjB (Tanaka et al., 2005; Kobori et al., 2004) and therefore they may block NF-jB translocation to the nucleus. Although all the ERK1/2, p38, and NF-jB inhibitors used in the present study significantly attenuated the enhanced ET B receptor expression on the VSMCs, respectively, their effects may occur through different intracellular signal pathways. Furthermore, they may directly inhibit the process of ET B receptor upregulation or indirectly block this process via up-and downregulation of other signal molecules like NO and AP-1. Interestingly, the SMOKE PARTICLES UPREGULATE ET B RECEPTORS 553 anti-inflammatory medication dexamethasone that is known to nonselectively inhibit NF-jB and AP-1 activity (Jeon et al., 2000) strongly diminished the DSP-induced upregulation of ET B receptors. Taken all together, we have demonstrated that the activation of intracellular MAPK ERK1/2 and NF-jB inflammatory signal pathways is mainly responsible for the DSP-induced upregulation of ET B receptors. However, we have recently determined that DSP induces thromboxane A 2 (TP) upregulation on the VSMCs with enhanced VSMC contraction. The upregulation of TP receptors by DSP occur via a posttranscriptional mechanism, mainly via enhanced translation of the receptor proteins and is independent of intracellular MAPK signaling (Zhang et al., 2008) .
DSP contains lipid-soluble smoke particles that can pass through the lung alveolar membrane into the blood and are transported by low density lipoprotein to the arterial wall to participate in atherosclerotic plaque formation (Shu and Bymun, 1983) . The WSP of cigarette smoke or nicotine per se did not induce changes in ET B receptor expression in the VSMCs. This agrees with epidemiological studies that have demonstrated when tobacco is smoked, it leads to a high incidence of atherosclerotic cardiovascular disease, while using moist snuff or nicotine replacement does not have as many associated cardiovascular risks (Huhtasaari et al., 1992 (Huhtasaari et al., , 1999 .
In conclusion, the present study has for the first time revealed that the expression of ET B receptors in VSMCs is upregulated by DSP via activation of intracellular MAPK (ERK1/2, p38) and NF-jB inflammatory signal pathways. The upregulation of VSMC ET B receptors enhances VSMC contraction and proliferation and thus may contributes to the development of cardiovascular disease. Understanding the underlying molecular mechanisms how the risk factors lead to cardiovascular disease may provide new options for the treatment. 
